WithdrawnPhase 2NCT00992173
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Principal Investigator
- Norman LaFrance, MDMolecular Insight Pharmaceutical Employee
- Intervention
- Ultratrace Iobenguane I 131(drug)
- Eligibility
- All sexes
- Timeline
- 2010
Study locations (21)
- Children's Hospital of LA, Los Angeles, California, United States
- UCSF Pediatric Hematology/Oncology, San Francisco, California, United States
- University of Miami Miller School of Medicine, Miami, Florida, United States
- Childrens Memorial/Northwestern University, Chicago, Illinois, United States
- Comer's Childrens Hospital/University of Chicago, Chicago, Illinois, United States
- University of iowa, Iowa City, Iowa, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Children's Hospital/Dana Farber Cancer Institute, Boston, Massachusetts, United States
- CS Motts Children's Hospital, Ann Arbor, Michigan, United States
- Mount Sinai School of Medicine, New York, New York, United States
- Hospital - Weill Cornell Medical Center, New York, New York, United States
- Memorial Sloan Kettering, New York, New York, United States
- Duke University Medical Center, Durham, North Carolina, United States
- Cincinnati Children's Hospital, Cincinnati, Ohio, United States
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
- +6 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00992173 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University